India Pharma Outlook Team | Friday, 30 October 2026
India’s pharma export numbers for the first half of FY27 reach USD 16.14 billion, a 4.9% rise from USD 15.38 billion a year earlier.
The modest headline figure, however, masks a sharper success: Europe, ASEAN and Latin America successfully offset moderating shipments to the US.
This geographic diversification now proves it is no longer a slogan but a working strategy.
US price pressure and inventory corrections continue to weigh on the largest market, yet rising European demand for affordable generics and biosimilars keeps overall pharma export momentum intact and reveals both resilience and the next challenge.
Overall pharma export earnings stand at USD 16.14 billion in H1 FY27. In the second quarter alone, shipments total USD 8.04 billion, up 3%. Regional contrasts make the diversification clear:
On the product side, bulk drugs and intermediates deliver the strongest category growth at 12%, while drug formulations and biologicals remain dominant at nearly 74% of shipments.
Also Read: India's 30% Anti-Cancer Drug Margin Cap: What It Means for Pharma
European governments push cost containment and substitute expensive brands with lower-cost generics and biosimilars under public procurement. Indian firms respond with deeper market engagement, stronger regulatory readiness, and reliable supply.
Pharmexcil Chairman Namit Joshi notes that Europe presents significant opportunities for collaboration. He stresses that combining India’s manufacturing and formulation expertise with global technological capabilities can open higher-value segments. The region’s steady demand therefore turns into a practical growth engine for Indian pharma exports.
Softness in the biggest market does not derail overall growth. Europe, ASEAN, Latin America and Africa together sustain the 4.9% rise and demonstrate the industry’s ability to spread risk. Yet the growth remains largely volume- and cost-driven.
Formulations still dominate at roughly 74% of total pharma export value. Sustainable acceleration requires a decisive move up the value chain into complex generics, biosimilars and specialized therapies. Greater investment in R&D, technology partnerships and co-development will decide whether the current resilience translates into higher-quality earnings.
India’s 4.9% rise shows the industry can weather US volatility through smarter geographic spread. Diversification has bought time and protected the overall pharma export trajectory. The next chapter will turn on whether Indian companies convert this resilience into higher-value exports. Innovation, not just volume, will determine the long-term path.
.jpg)
